PE
VKTX icon

Point72 Europe’s Viking Therapeutics VKTX Stock Holding History

Point72 Europe’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$1.66K Buy
+63
New +$1.88K ﹤0.01% 676

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Europe's VKTX Position: Q3 2025 in Review

Point72 Europe opened a new position in Viking Therapeutics (VKTX) in Q3 2025: 63 shares worth $1.66K. The stake represents ﹤0.01% of the portfolio and ranks #676 among its holdings.

370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

  • Point72 Europe held 63 shares of Viking Therapeutics worth $1.66K as of Q3 2025.
  • Viking Therapeutics was a new Point72 Europe position in Q3 2025.
  • Viking Therapeutics made up ﹤0.01% of Point72 Europe's portfolio in Q3 2025, its #676 holding.
  • 370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.